Table 1.

Regulatory inputs and functional responses of demonstrated DAT phosphorylation sites.

In vivo site	Increased phosphorylation	Outcome	Decreased phosphorylation	Outcome
PKC domain	PKC activators	↓DA uptake Vmax(g,h,l,n)	PKC inhibitors	↑DA uptake Vmax(b,l,m)
	AMPH, METH	↑DA efflux Vmax(e,i,j)	Δ21/22 truncation	↓PKC-induced down-regulation(f,n)
	PP1 inhibitors	↑PKC-induced down-regulation(f)	Palmitoylation enhancers	↓AMPH-induced efflux(h,i,m)
	Palmitoylation inhibitors	↑CFT affinity(k)	Botulinum neurotoxin C	↓AMPH-induced down-regulation(a)
Ser7	PKC activators	↓DA uptake Vmax(l)	S7A mutation	↑DA uptake Vmax(l)
	C580A mutation	↓Cys580 palmitoylation(l)		↓AMPH-induced efflux(j,n,o,p)
	Palmitoylation inhibitors	↑CFT affinity(l)		↓PKC-induced down-regulation(f)
				↑Cys580 palmitoylation(l)
				↓CFT affinity(l)
Thr53	PIN1 inhibitors	↑DA efflux(d)	T53A mutation	↓DA uptake Vmax(c,f)
	PKC activators			↓AMPH-induced MPP+ efflux(f)
	AMPH, METH			↑AMPH-induced DA efflux(c)
	PP1/2A inhibitors			↓CFT affinity(c)

Superscripts denote references for studies that link the indicated outcomes to one or more of the conditions that increase or decrease phosphorylation of specified sites:

^aCervinski et al. 2005

^bCervinski et al., 2010

^cChallasivikanaka et al 2012

^dChallasivikanaka et al 2014

^eFog et al., 2005

^fFoster et al., 2012

^gGranas et al., 1995

^hHuff et al., 1997

ⁱJohnson et al., 2005

^jKhoushbouie et al., 2004

^kMoritz et al., 2013

^lMoritz et al. 2015

^mRastedt et al., 2016

ⁿVaughan et al., 1997

^oWang et al., 2016

^pZhen et al., 2012.